Clinical trial
Open access
Blood‐based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG‐GY012
Andrew B. Nixon
Danielle M. Enserro
D. Bender
Ying-Miao Liu
Mark D. Starr
J. Brady
J. Gonzalez Bosquet
B. Rimel
L. Holman
C. Rivard
D. Veljovich
Julia Fehniger
J. Moroney
F. Backes
M. Cadungog
Matthew A. Powell
Tara Castellano
A. A. Secord
H. MacKay
Medicine
Abstract
The NRG‐GY012 phase 2 trial evaluated olaparib, cediranib, and the combination in 120 patients with recurrent, persistent, or metastatic endometrial cancer (EC). Predictive and prognostic associations between blood‐based biomarkers and clinical outcomes were assessed.